Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant.
about
Liposome-Based Adjuvants for Subunit Vaccines: Formulation Strategies for Subunit Antigens and ImmunostimulatorsTargeting the innate immune system as immunotherapy for acute myeloid leukemiaNanomedicine in the application of uveal melanomaThe era of bioengineering: how will this affect the next generation of cancer immunotherapy?VISTA Regulates the Development of Protective Antitumor Immunity.Transfected poly(I:C) activates different dsRNA receptors, leading to apoptosis or immunoadjuvant response in androgen-independent prostate cancer cellsPoly(I:C) induces antiviral immune responses in Japanese flounder (Paralichthys olivaceus) that require TLR3 and MDA5 and is negatively regulated by Myd88.Inactivated Eyedrop Influenza Vaccine Adjuvanted with Poly(I:C) Is Safe and Effective for Inducing Protective Systemic and Mucosal Immunity.Examination of a Viral Infection Mimetic Model in Human iPS Cell-Derived Insulin-Producing Cells and the Anti-Apoptotic Effect of GLP-1 AnalogueThe tumor protection effect of high-frequency administration of whole tumor cell vaccine and enhanced efficacy by the protein component from Agrocybe aegerita.Chitosan-Poly (I:C)-PADRE Based Nanoparticles as Delivery Vehicles for Synthetic Peptide VaccinesCharacterization of Innate Responses Induced by PLGA Encapsulated- and Soluble TLR Ligands In Vitro and In Vivo in Chickens.Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose.Toll-like receptor 3-induced immune response by poly(d,l-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy.Peptide/protein vaccine delivery system based on PLGA particles.Physicochemical and functional characterization of vaccine antigens and adjuvants.The gut flora is required for the control of intestinal infection by poly(I:C) administration in neonates.Vaccine adjuvant uses of poly-IC and derivatives.Dendritic cell-based vaccine research against cancer.Nucleic acid binding and other biomedical properties of artificial oligolysines.Preparation and in vitro evaluation of imiquimod loaded polylactide-based micelles as potential vaccine adjuvants.Production of Adjuvant-Loaded Biodegradable Particles for Use in Cancer Vaccines.Identification and evaluation of the novel immunodominant antigen Rv2351c from Mycobacterium tuberculosis.Synthetic nanovaccines for immunotherapy.Co-delivery of polyinosinic:polycytidylic acid and flagellin by poly(lactic-co-glycolic acid) MPs synergistically enhances immune response elicited by intranasally delivered hepatitis B surface antigen.The type of adjuvant strongly influences the T-cell response during nanoparticle-based immunization.Elevated sodium chloride drives type I interferon signaling in macrophages and increases antiviral resistance.Synergistic effects of stellated fibrous mesoporous silica and synthetic dsRNA analogues for cancer immunotherapy.Integration of nano drug-delivery system with cancer immunotherapy.Strong in vivo antitumor responses induced by an antigen immobilized in nanogels via reducible bonds.Increase in CTGF mRNA expression by respiratory syncytial virus infection is abrogated by caffeine in lung epithelial cells.Intranasal administration of a two-dose adjuvanted multi-antigen TMV-subunit conjugate vaccine fully protects mice against Francisella tularensis LVS challenge.Soluble TNF-like weak inducer of apoptosis (TWEAK) enhances poly(I:C)-induced RIPK1-mediated necroptosis
P2860
Q26765446-5FD8A5C9-C77F-4B34-B7A1-0EF3B248AAC1Q27015876-B264AE19-436C-4CC1-B40D-DE6839ED6C5FQ28079572-8EE8B9C1-7730-4770-AFDA-AD9AFD61A288Q33815087-5AF7ECBC-B479-45D1-ADD1-708D3826B7F5Q33978040-F6518EDB-DB03-4CEC-A9FD-96770442E390Q35126624-C8376841-B9FE-441D-BD84-FE96E4CEC558Q35417313-92B12ED6-2AE9-4394-AB70-DF56D0AED832Q35768825-E73A063D-F65B-451F-9017-95875D725322Q35867232-09A6A39F-816A-4DD5-AC43-7904AD910FD3Q35870629-1915A4D9-E13C-424D-B86E-5FA61E2D0537Q36101913-7663292A-970D-44CE-91FC-DC76CA59AD66Q36238084-A563008B-7A06-406B-8706-A632479390C4Q37377550-98E26E5F-8119-4B81-9E3F-FAE7902B5A8CQ37398348-EF4E56A0-54DE-4833-A535-EB01BF95A8B1Q37838652-10068FEB-9D7D-4988-B6CA-4D576063E737Q38202170-6A43C913-C2EA-4D06-9A3F-558E63555988Q38219472-2A8E3122-01F2-453A-A13A-6E2233254FBEQ38259510-F5FB3C53-6DBA-480D-BF35-05A62BC9471DQ38281782-2A420E5D-7787-41FC-B430-EA48043E22F5Q38289336-DBE5B07B-CEE9-4966-B03F-00D9541EA0EAQ38953988-56812FFE-1F91-4894-B1E9-36095A83B451Q39310298-4FDD93B7-973A-42D9-86E5-C566E396A2ECQ40170246-6018919E-ED41-4CE0-998C-D34E73305679Q40280801-3887B291-97FB-4085-A641-935E7AD07671Q41225913-41FBA8FD-FBB7-428F-AFAC-AB38AED7500DQ42249644-8AF557A1-1C4F-4EAC-A681-43B00EBA3ACEQ47371006-458BB56B-E7E5-4C3C-AF0A-C53F56C757CDQ47738760-62550099-ACBA-46E7-8E5B-60FE90297AB4Q48622958-90F4A11B-0182-4614-8A29-287C8D21AB34Q48974238-103E61EA-6DBF-4D17-82E1-45B52ADDF5A8Q54234953-478C1203-AF7B-42C2-B4D3-3ED9BAE330ECQ55001017-D012BFFE-FC98-4ECD-AE2B-B5D38DB1ED22Q57801740-C01834D5-6218-41C4-94E6-87FC403EC5A1
P2860
Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant.
@en
type
label
Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant.
@en
prefLabel
Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant.
@en
P2093
P1476
Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant.
@en
P2093
Annina M Hafner
Blaise Corthésy
Hans P Merkle
P304
P356
10.1016/J.ADDR.2013.05.013
P407
P577
2013-06-07T00:00:00Z